Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOWTRL)

Drug Name

GSK-2315698 Drug Info

Synonyms

GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serum amyloid P-component (APCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zinpentraxin alfa	DMNJAVV	Idiopathic pulmonary fibrosis	CB03.4	Phase 3	[3]
CPHPC	DM1ZGUX	Parkinson disease	8A00.0	Phase 1/2	[4]
GSK2398852	DMZ5A6D	Amyloidosis	5D00	Phase 1	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum amyloid P-component (APCS)	TTB7VAT	SAMP_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
2	Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.
3	Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023 Oct 1;108(10):2730-2742.
4	Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).Acta Crystallogr D Biol Crystallogr.2014 Aug;70(Pt 8):2232-40.